Intracellular Oncoproteins Can Be Targeted by Mutation-Specific Dimeric IgA

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cytoplasmic oncodrivers are key targets in cancer therapy.
• Dimeric IgA (dIgA) offers unique therapeutic potential due to its structure and effector functions.
• Engineering dIgA for specific intracellular targeting remains a challenge.

Purpose of the Study:

• To engineer dIgA antibodies capable of targeting mutated cytoplasmic oncodrivers.
• To evaluate the efficacy of engineered dIgA in abrogating tumor growth.

Main Methods:

• Development of dIgA constructs with specificity for intracellular oncodriver mutations.
• In vitro and in vivo models to assess dIgA delivery and anti-tumor activity.
• Analysis of tumor growth inhibition and potential mechanisms of action.

Main Results:

• Engineered dIgA successfully targeted mutated cytoplasmic oncodrivers.
• Significant abrogation of tumor growth was observed in treated models.
• Demonstrated the potential for intracellular antibody-based cancer therapy.

Conclusions:

• Engineered dIgA represents a promising strategy for targeting intracellular oncogenic drivers.
• This approach offers a novel therapeutic avenue for cancers driven by specific mutations.
• Further development could lead to new treatments for various malignancies.